We further tested the therapeutic effects of L-NAME in a transgenic EGFP-HDQ71 zebrafish model of HD [Tg(rho:EGFP-HTT71Q)cu5] by assessing mutant huntingtin aggregates in the retina where the transgene is driven by the rhodopsin promoter (Williams et al., 2008). This evidence concerns the gene RHO and Huntington disease.